560 results on '"Klivényi, Péter"'
Search Results
102. Neuronal and glial CSF biomarkers in multiple sclerosis
103. Additional file 1 of Genetic epidemiological characteristics of a Hungarian subpopulation of patients with Huntington’s disease
104. Additional file 2 of Genetic epidemiological characteristics of a Hungarian subpopulation of patients with Huntington’s disease
105. Kynurenines in Parkinson’s disease: therapeutic perspectives
106. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease
107. Two Classes of T1 Hypointense Lesions in Multiple Sclerosis With Different Clinical Relevance
108. NEAT1 on the Field of Parkinson’s Disease: Offense, Defense, or a Player on the Bench?
109. Additional file 2 of Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain
110. Additional file 1 of Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund’s adjuvant model of orofacial pain
111. Rare complication of West Nile viral encephalitis
112. Atypical presentation of late-onset Sandhoff disease : A case report
113. A Magyar Klinikai Neurogenetikai Társaság konszenzusajánlása a felnőttkori spinalis izomatrophia (SMA) kezeléséhez
114. Az epilepsziás betegek ellátásának változása a COVID–19-járvány első veszélyhelyzeti periódusában
115. Web‐based decision support system for patient‐tailored selection of antiseizure medication in adolescents and adults: An external validation study.
116. Mice lacking alpha-synuclein are resistant to mitochondrial toxins
117. Nonenzymatic antioxidants of blood in multiple sclerosis
118. Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines
119. Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase Influenced the Age Onset of Parkinson’s Disease
120. Altered brain network function during attention-modulated visual processing in multiple sclerosis
121. Wild Bitter Melon Exerts Anti-Inflammatory Effects by Upregulating Injury-Attenuated CISD2 Expression following Spinal Cord Injury
122. Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase 1 Influenced the Age Onset of Parkinson’s Disease
123. Fixed-dose combination therapy for Parkinson’s disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime
124. Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the ATP6V1B2 Gene
125. Non-invasive Brain Stimulation in Alzheimer's Disease and Mild Cognitive Impairment—A State-of-the-Art Review on Methodological Characteristics and Stimulation Parameters
126. Neurotransmitter and tryptophan metabolite concentration changes in the Complete Freund’s adjuvant model of orofacial pain
127. Epidemiology of multiple sclerosis in Central Europe, update from Hungary
128. Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson’s disease
129. Légzési elégtelenséggel járó CANOMAD szindróma
130. Late simultaneous carcinomatous meningitis, temporal bone infiltrating macro-metastasis and disseminated multi-organ micro-metastases presenting with mono-symptomatic vertigo – a clinico-pathological case reporT
131. Az előrehaladott Parkinson-kór jellemzői a klinikai gyakorlatban: az OBSERVE-PD vizsgálat eredményei és a magyarországi alcsoport elemzése
132. Neuroprotection in Parkinson’s disease: facts and hopes
133. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntingtonʼs disease
134. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease
135. Increased glucose metabolism and ATP level in brain tissue of Huntingtonʼs disease transgenic mice
136. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase
137. Altered brain network function during attention-modulated visual processing in multiple sclerosis.
138. DIFFERENCIAL DIAGNOSIS BETWEEN PARKINSONS DISEASE AND PARKINSONIAN SYNDROMES WITH 99m Tc TRODAT SPECT: WE 97
139. Opicapone for the treatment of Parkinson’s disease: an update
140. The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials
141. Predominant neurological phenotype in a Hungarian family with two novel mutations in the XPA gene—case series
142. Comprehensive Genetic Analysis of a Hungarian Amyotrophic Lateral Sclerosis Cohort
143. Zonisamidkezelés myoclonusdystoniában
144. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson’s disease patients
145. Angiogenin mutations in Hungarian patients with amyotrophic lateral sclerosis: Clinical, genetic, computational, and functional analyses
146. Multiplex ischaemiás stroke Osler-Rendu-Weber-kórban
147. Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease
148. Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease
149. Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund's adjuvant model of orofacial pain.
150. CANOMAD SYNDROME WITH RESPIRATORY FAILURE.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.